Insulin Glargine 100 Units/mL Alone or in Combination with Short-Acting Insulin in the Management of Uncontrolled Type 2 Diabetes Mellitus: A Prospective Real-Life Study from Egypt (DIAMOND)

Abstract

Abstract Background: Recent reports reveal growing evidence of the effectiveness of insulin glargine (Lantus®), a long-acting human insulin analogue, in the management of poorly con-trolled type 2 diabetes mellitus (T2DM). In the present real-life study.Aim of the Study: To investigate the safety and efficacy of insulin glargine in treating patients with T2DM that are poorly controlled on oral anti-diabetic drugs (OADs).Subjects and Methods: In this prospective observational study conducted in Egypt from 2014 to 2016, a total of 1008 people with poorly controlled T2DM were enrolled, and for whom the investigator decided to prescribe insulin glargine with or without short-acting insulin. The decision of adding-on OADs or short-acting insulin was left to the investigators to reflect the in-practice approach. Patients were followed up for six months and efficacy and safety outcomes were measured throughout the study period. The primary efficacy endpoint was the change in HbA1c levels from the baseline to the final visit. Results: At the end of follow-up, the mean HbA1c levels decreased significantly from 9.6±1.3% at the baseline to 7.3±0.9% (p 0.05). A total of 17 hypoglycemia events (11 categorized as serious) and one hyperglycemic event were recorded.Conclusion: Under real-world clinical practice insulin glargine 100U/ml as add-on to OADs, or in combination with prandial insulin, demonstrated a good efficacy and safety profile in people with T2DM uncontrolled previous on OAD therapy.